Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. T…
Biotechnology
US, Waltham [HQ]
APLS/Financial Reporting
Income Statements
11 Sheets · Starting from 2023In Million USD. Margins, Growth Rates In %
| Metric | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - - | - - | - - | - - | - - | - - | - - | 250.00 | 66.00 | 75.00 | 396.00 | |
|
EPS
|
-0.22 | -0.60 | -2.57 | -1.50 | -3.68 | -2.34 | -4.98 | -4.59 | -8.84 | -6.15 | -4.45 | |
| Diluted in mil. | -0.22 | -0.60 | -2.57 | -1.50 | -3.68 | -2.34 | -4.98 | -4.59 | -8.84 | -6.15 | -4.45 | |
|
Profit
|
- - | - - | - - | - - | -50.00 | -127.00 | -288.00 | 225.00 | 61.00 | 69.00 | 336.00 | |
| Gross Margin | - - | - - | - - | - - | - - | - - | - - | 90.01 | 92.19 | 92.53 | 84.82 | |
| Pre Tax | -3.00 | -11.00 | -46.00 | -27.00 | -51.00 | -127.00 | -304.00 | -343.00 | -746.00 | -651.00 | -526.00 | |
| Profit Margin | - - | - - | - - | - - | - - | - - | - - | -136.86 | -1,120.75 | -863.81 | -132.76 | |
| ETR | - - | 3.95 | 57.05 | - - | -0.49 | 0.42 | -1.68 | -0.54 | -0.05 | -0.10 | -0.40 | |
| Net | -3.00 | -10.00 | -46.00 | -27.00 | -51.00 | -127.00 | -309.00 | -344.00 | -746.00 | -652.00 | -528.00 | |
| Profit Margin | - - | - - | - - | - - | - - | - - | - - | -137.59 | -1,121.27 | -864.70 | -133.29 | |
| EBITDA | -4.00 | -11.00 | 6.00 | -27.00 | -50.00 | -125.00 | -282.00 | -209.00 | -533.00 | -584.00 | -515.00 | |
| EBITDA Margin | - - | - - | - - | - - | - - | - - | - - | -83.55 | -800.75 | -774.97 | -129.96 | |
| Operating Income | -4.00 | -11.00 | -46.00 | -27.00 | -50.00 | -127.00 | -288.00 | -213.00 | -536.00 | -594.00 | -517.00 | |
| Operating Margin | - - | - - | - - | - - | - - | - - | - - | -85.27 | -805.67 | -788.38 | -130.39 | |
| Interest Income | - - | - - | - - | - - | - - | 2.00 | 5.00 | 4.00 | - - | 8.00 | 20.00 | |
| Loss | -4.00 | -11.00 | -20.00 | -27.00 | -50.00 | -127.00 | -288.00 | -464.00 | -602.00 | -670.00 | -913.00 | |
| Cost of Revenue | - - | - - | - - | - - | -50.00 | -127.00 | -288.00 | -25.00 | -5.00 | -5.00 | -60.00 | |
|
Operating Expenses
|
-4.00 | -11.00 | -20.00 | -27.00 | -50.00 | -127.00 | -288.00 | -439.00 | -597.00 | -664.00 | -853.00 | |
| R&D | -2.00 | -8.00 | -13.00 | -22.00 | -40.00 | -105.00 | -220.00 | -299.00 | -420.00 | -387.00 | -354.00 | |
| G&A | -1.00 | -2.00 | -6.00 | -4.00 | -10.00 | -22.00 | -67.00 | -139.00 | -176.00 | -277.00 | -500.00 | |
| SG&A | -1.00 | -2.00 | -6.00 | -4.00 | -10.00 | -22.00 | -67.00 | -139.00 | -176.00 | -277.00 | -499.00 | |
| S&M | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | -1.00 | |
| Depreciation and Amortization | - - | - - | - - | - - | - - | - - | - - | - - | -1.00 | -1.00 | -1.00 | |
| Interest Expenses | - - | - - | - - | - - | - - | -2.00 | -5.00 | -29.00 | -13.00 | -32.00 | -29.00 | |
| Other Expenses | - - | - - | -26.00 | - - | - - | - - | -16.00 | -129.00 | -209.00 | -56.00 | -9.00 | |
|
WA Shares Outstanding
|
18.00 | 18.00 | 18.00 | 18.00 | 13.00 | 54.00 | 62.00 | 75.00 | 84.00 | 106.00 | 118.00 | |
| Diluted | 18.00 | 18.00 | 18.00 | 18.00 | 13.00 | 54.00 | 62.00 | 75.00 | 84.00 | 106.00 | 118.00 |